01
The most common side effects of bicalutamide monotherapy in men include breast
Gynecomastia is the benign enlargement of male breast glandular tissue and is the most
It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC)
Gynecomastia (GM) is a benign unilateral or bilateral enlargement of male breast, which results from glandular tissue proliferation [1, 2]
A careful breast examination is the first step to distinguishing true gynecomastia (enlargement of the glandular tissue) from pseudogynecomastia (excessive adipose tissue) ( figure 1 )
Thus, the most troublesome side
19
Parallel to female breast development, estrogen, growth hormone (GH), and IGF-1 are required
Bicalutamide is an appealing alternative to flutamide for the treatment of androgen-dependent skin and hair conditions in women because flutamide has a considerable risk of serious liver toxicity, However, gynecomastia, attributed to bicalutamide, was observed in almost half of the boys
Last edited dd mmm yyyy
Gynecomastia developed in 73% of patients in the bicalutamide group, 10% of patients in the bicalutamide–tamoxifen group and 51% in the bicalutamide–anastrozole group
Arm 1) bicalutamide 150 mg alone vs
Background: Gynaecomastia and breast pain are frequent adverse events with bicalutamide monotherapy, and might cause some patients to withdraw from treatment
Bicalutamide-induced gynecomastia can be prevented by or treated with SERMs
Gynecomastia is a benign proliferation of glandular tissue in the male breast
However, this treatment induces gynecomastia in most patients, which often results in treatment discontinuation